Literature DB >> 18342532

Indications and outcome of salvage surgery for oesophageal cancer.

Xavier-Benoit D'Journo1, Pierre Michelet, Laetitia Dahan, Christophe Doddoli, Jean-François Seitz, Roger Giudicelli, Pierre A Fuentes, Pascal A Thomas.   

Abstract

OBJECTIVE: Some patients with localised oesophageal cancer are treated with definitive chemoradiotherapy (CRT) rather than surgery. A subset of these patients experiences local failure, relapse or treatment-related complication without distant metastases, with no other curative treatment option but salvage oesophagectomy. The aim of this study was to assess the benefit/risk ratio of surgery in such context.
METHODS: Review of a single institution experience with 24 patients: 18 men and 6 women, with a mean age of 59 years (+/-9). Histology was squamous cell carcinoma in 18 cases and adenocarcinoma in 6. Initial stages were cIIA (n=5), cIIB (n=1) and cIII (n=18). CRT consisted of 2-6 sessions of the association 5-fluorouracil/cisplatin concomitantly with a 50-75 Gy radiation therapy. Salvage oesophagectomy was considered for the following reasons: relapse of the disease with conclusive (n=11) or inconclusive biopsies (n=7), intractable stenosis (n=3), and perforation or severe oesophagitis (n=3), at a mean delay of 74 days (14-240 days) following completion of CRT.
RESULTS: All patients underwent a transthoracic en-bloc oesophagectomy with 2-field lymphadenectomy. Thirty-day and 90-day mortality rates were 21% and 25%, respectively. Anastomotic leakage (p=0.05), cardiac failure (p=0.05), length of stay (p=0.03) and the number of packed red blood cells (p=0.02) were more frequent in patients who received more than 55 Gy, leading to a doubled in-hospital mortality when compared to that of patients having received lower doses. A R0 resection was achieved in 21 patients (87.5%). A complete pathological response (ypT0N0) was observed in 3 patients (12.5%). Overall and disease-free 5-year survival rates were 35% and 21%, respectively. There was no long-term survivor following R1-R2 resections. Functional results were good in more than 80% of the long-term survivors.
CONCLUSION: Salvage surgery is a highly invasive and morbid operation after a volume dose of radiation exceeding 55 Gy. The indication must be carefully considered, with care taken to avoid incomplete resections. Given that long-term survival with a fair quality of life can be achieved, such high-risk surgery should be considered in selected patients at an experienced centre.

Entities:  

Mesh:

Year:  2008        PMID: 18342532     DOI: 10.1016/j.ejcts.2008.01.056

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  17 in total

Review 1.  Endoscopic submucosal dissection for malignant esophageal lesions.

Authors:  Hazem Hammad; Tonya Kaltenbach; Roy Soetikno
Journal:  Curr Gastroenterol Rep       Date:  2014

2.  Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy.

Authors:  Hiroya Takeuchi; Yoshiro Saikawa; Takashi Oyama; Soji Ozawa; Koichi Suda; Norihito Wada; Tsunehiro Takahashi; Rieko Nakamura; Naoyuki Shigematsu; Nobutoshi Ando; Masaki Kitajima; Yuko Kitagawa
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

3.  Accomplishments in 2008 in the management of esophageal cancer.

Authors:  Gary Y Yang; Katja Ott
Journal:  Gastrointest Cancer Res       Date:  2009-09

Review 4.  Current management of esophageal cancer.

Authors:  Xavier Benoit D'Journo; Pascal Alexandre Thomas
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

5.  Lymphadenectomy via a cervical approach for upper mediastinal lymph node recurrence of esophageal cancer: report of a case.

Authors:  Hiroyuki Tada; Atsushi Shiozaki; Hitoshi Fujiwara; Daisuke Ichikawa; Kazuma Okamoto; Shuhei Komatsu; Yasutoshi Murayama; Hisashi Ikoma; Yoshiaki Kuriu; Masayoshi Nakanishi; Toshiya Ochiai; Yukihito Kokuba; Teruhisa Sonoyama; Eigo Otsuji
Journal:  Surg Today       Date:  2011-10-04       Impact factor: 2.549

6.  Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma.

Authors:  K Fakhrian; M Oechsner; S Kampfer; T Schuster; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

7.  Hyperglycemia 3 days after esophageal cancer surgery is associated with an increased risk of postoperative infection.

Authors:  Naoko Ito; Takeshi Iwaya; Kenichiro Ikeda; Yusuke Kimura; Yuji Akiyama; Masafumi Konosu; Kaoru Ishida; Hisataka Fujiwara; Koki Otsuka; Hiroyuki Nitta; Masahiro Kashiwaba; Keisuke Koeda; Satoshi Nishizuka; Masaru Mizuno; Akira Sasaki; Go Wakabayashi
Journal:  J Gastrointest Surg       Date:  2014-07-04       Impact factor: 3.452

8.  Efficacy of the endoscopic management of postoperative fistulas of leakages after esophageal surgery for cancer: a retrospective series.

Authors:  Jean-Michel Gonzalez; C Servajean; B Aider; M Gasmi; X B D'Journo; M Leone; J C Grimaud; M Barthet
Journal:  Surg Endosc       Date:  2016-03-04       Impact factor: 4.584

9.  MiR-21 down-regulation suppresses cell growth, invasion and induces cell apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal carcinoma.

Authors:  Na Wang; Chao-Qi Zhang; Jia-Huan He; Xiao-Fei Duan; Yuan-Yuan Wang; Xiang Ji; Wen-Qiao Zang; Min Li; Yun-Yun Ma; Tao Wang; Guo-Qiang Zhao
Journal:  Dig Dis Sci       Date:  2013-03-17       Impact factor: 3.199

10.  Tracheobronchial lesions following esophagectomy: erosions, ulcers, and fistulae, and the predictive value of lymph node-related factors.

Authors:  Kiyotomi Maruyama; Satoru Motoyama; Yusuke Sato; Kaori Hayashi; Shuetu Usami; Yoshihiro Minamiya; Jun-ichi Ogawa
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.